Description
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
This trial is available at multiple Sutter Locations. Please contact one of the following about Study ECOG-ACRIN EA8183
San Francisco: ClinicalResearch@sutterhealth.org
Palo Alto/Santa Cruz: Tanya Pozniansky pozniat@sutterhealth.org
PAMF/Fremont: Tanya Pozniansky pozniat@sutterhealth.org
East Bay: Vivian Leong, RN Leongv@sutterhealth.org
Sacramento: Kirsten Babski babskik@sutterhealth.org
Modesto: Adrienne Palos PalosA@sutterhealth.org
Solano-Vallejo Cancer Center: Stephanie Gonzales gonzals1@sutterhealth.org
San Mateo: Stephanie Casal CasalSL@sutterhealth.org and Bonnie Chan ChanBW@sutterhealth.org
Santa Rosa: Patricia Grinnell GrinneP@sutterhealth.org
Principal Investigator
Recruitment Status
Active, Recruiting
Start Date
February 19, 2021
Research Topics
Related Studies
Genomic Health Oncotype DX AR-V7
Investigators: Vijay Suhag, M.D., Brian K. Kim, M.D, Rajeswari Chellappah, M.D., Sivakumar Reddy, M.D., David S Yee, M.D., MPH, Nitin Rohatgi, MD, Kristie A. Bobolis, M.D., Kristin N. Arreola, M.D.